Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

Amicus Makes Steady Progress Toward Achievement of Milestones

CRANBURY, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the third quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.36 per share ($0.29 per share on a non-GAAP basis) for the three months ended September 30, 2008. As of September 30, 2008, cash, cash equivalents, and marketable securities totaled $136.3 million.

"The third quarter of 2008 was another quarter of strong progress for Amicus as we focused on clinical and regulatory execution on our three lysosomal storage disease programs," said John F. Crowley, President and CEO of Amicus Therapeutics. "In recent months, we have continued the process with regulatory authorities in the United States and Europe in order to define the global development plan for Amigal(TM) in Fabry, and we remain on track to provide an update by the end of the year. In our Gaucher and Pompe disease programs, we continue to focus on advancing our ongoing Phase 2 clinical trials with the goal of reporting data in Gaucher in 2009. Finally, our financial position remains strong based on a healthy balance sheet and on the economics from our strategic alliance with Shire, which funds 50% of development costs for our lead programs in addition to success-based clinical and regulatory milestone payments."

Program Advancements

Fabry Disease:

Amigal (migalastat hydrochloride) is an investigational, oral therapeutic being developed for the treatment of Fabry disease. Amicus, along with its partner Shire Human Genetic Ther
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... The Americas Inorganic Refrigerants Market report ... Americas with analysis and forecast of revenue. , ... Refrigerants Market report, to get an idea of ... glimpse of the segmentation in the Americas inorganic ... and figures. , http://www.micromarketmonitor.com/market/americas-inorganic-refrigerants-4191654241.html , ...
(Date:10/22/2014)... October 22, 2014 Currently offering ... A & D Weighing, Rice Lake, and Ohaus, ... Balance . The Sartorius CPA Semi-Micro Balance is ... high-quality, precise, and user-friendly laboratory balance. , Sartorius ... equipment, their laboratory balances are well known for ...
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/20/2014)... 2014 Mapp Biopharmaceutical,s valiant effort to ... to fight the Ebola outbreak will make the ... production of pharmaceuticals can be, according to Kalorama ... while some may be taken aback by the ... industry knowledge are well aware of the complex ...
Breaking Biology Technology:The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... of Madison has been licensed to sell a ... agents, GenTel announced on Tuesday. , ,GenTel will market ... Kreatech Biotechnology BV of Amsterdam, under its ... are validated for use on GenTel's PATH protein microarray ...
... drive thru Illinois you now pay a premium for using cash ... device for your car. If you stop for gas at a ... plastic device on their key chain to pay for gas. These ... applications to reduce costs, improve efficiency, and potentially improve the buyers ...
... Wis. - Former Wisconsin Gov. and Secretary of ... board of directors at C.R. Bard , the ... at the company's August board meeting. , ,Bard, a ... sells specialty devices for vascular, urology, oncology and surgical ...
Cached Biology Technology:
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
(Date:10/16/2014)... wages war on the human body. Battles are ... In pancreatic cancer, this stalemate—known as tumor dormancy—can ... malignant, a phenomena that is poorly understood. ... laboratory of Salvatore Torquato, a Professor of Chemistry ... surrounding tumor dormancy and the switch to a ...
(Date:10/16/2014)... cultivated efficiently, they are anything but sustainable: environmental ... cultivation is becoming increasingly evident. Despite their disadvantages, ... are regarded as the sole possibility of achieving ... finds Bernhard Schmid, an ecology professor at the ... of agriculture and forestry. After all, a new ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... is measured to understand tree health, fluxes in carbon ... of the most essential and widely collected woody plant ... is awkward and time consuming. Scientists have developed a ... safely and accurately. Dendrometer bands are metal straps ...
... (IL-7) is an important immune messenger protein which ensures ... in our body for immune defence. Researchers from ETH ... function: it enhances the drainage function of lymphatic vessels, ... vessels into the body tissue and return it to ...
... an old dog new tricks." Now neuroscientists are beginning to ... neuroscientists have struggled to understand how the microcircuitry of the ... for the old. New findings published in the journal ... Los Angeles and the University of California, Irvine show how ...
Cached Biology News:New technique for measuring tree growth cuts down on research time 2New technique for measuring tree growth cuts down on research time 3New function for a well-known immune messenger molecule 2New function for a well-known immune messenger molecule 3Researchers discover how inhibitory neurons behave during critical periods of learning 2
... HISTAR detection systems provide linking and ... with species specific primary antibodies for ... Visualisation is accomplished using an ultra-sensitive ... polymer labelling technology. Secondary antibodies are ...
... Enzyme concentration - 5 units/µL ,• High ... yields ,• Leaves an 'A' overhang ,• ... which exhibits very high activity in primer ... ensure the quality of the enzyme, each ...
... from Thermus aquaticus expressed in E. coli; ... of 250 units enzyme/tube and Buffer I ... the same enzyme as AmpliTaq DNA Polymerase ... separation process to ensure that contaminating bacterial ...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
Biology Products: